Phase 2 Readout
IMMX: Phase 2 Readout: nxc-201
September 30, 2026 · nxc-201. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 30, 2026
- Company
- Immix Biopharma, Inc. (IMMX)
- Drug
- nxc-201
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Readout
Phase 2 Readout: nxc-201
- Company
- Immix Biopharma, Inc. (IMMX)
- Drug
- nxc-201
- Indication
- relapsed/refractory AL Amyloidosis